Drug intelligence / Profile preview

IDC331

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IDC331 is a novel concept monoclonal antibody being developed by Prestige Biopharma for the treatment of solid tumors. It is part of the company's innovative drug pipeline and is currently in the preclinical stage of development. As of early 2024, the candidate has successfully demonstrated proof of concept (PoC) in preclinical studies. While the specific molecular target and mechanism of action have not been publicly disclosed by the developer, the drug is categorized as a 'Novel Concept Antibody' aimed at addressing unmet needs in oncology.

Beyond the preview

Go deeper on IDC331.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC331.

Explore the full profile